Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Theravance (THRX) said FDA's Anti-Infective Drugs Advisory Committee may soon meet to review an NDA for telavancin to treat complicated
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury